# An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options

> **NCT04739150** · — · NO_LONGER_AVAILABLE · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Lung Diseases, Interstitial

## Interventions

- **DRUG:** nintedanib

## Key facts

- **NCT ID:** NCT04739150
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04739150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04739150, "An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04739150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*